Molecular Partners AG ADR (MOLN) — Cash Flow-to-Debt Ratio
Molecular Partners AG ADR (MOLN) has a Cash Flow-to-Debt Ratio of -0.49x as of December 2025, meaning its operating cash flow of $-10.67 Million could theoretically repay 0% of its total liabilities ($21.77 Million) in one year. Check Molecular Partners AG ADR total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Molecular Partners AG ADR Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Molecular Partners AG ADR across 13 annual periods. Also explore MOLN total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Molecular Partners AG ADR (2013–2025)
Year-by-year debt coverage analysis for Molecular Partners AG ADR. For market capitalisation and broader financial context, see Molecular Partners AG ADR market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.35x | $-51.26 Million | $21.77 Million | ▲ +32.9% |
| 2024 | -3.51x | $-59.25 Million | $16.89 Million | ▼ -30.3% |
| 2023 | -2.69x | $-59.01 Million | $21.92 Million | ▼ -161.5% |
| 2022 | 4.38x | $118.57 Million | $27.09 Million | ▲ +414.6% |
| 2021 | -1.39x | $-90.95 Million | $65.38 Million | ▼ -285.6% |
| 2020 | -0.36x | $-28.98 Million | $80.33 Million | ▼ -1441.5% |
| 2019 | -0.02x | $-1.19 Million | $50.80 Million | ▲ +96.5% |
| 2018 | -0.67x | $-42.47 Million | $63.45 Million | ▲ +53.7% |
| 2017 | -1.45x | $-40.02 Million | $27.69 Million | ▼ -97.3% |
| 2016 | -0.73x | $-35.38 Million | $48.30 Million | ▼ -286.9% |
| 2015 | 0.39x | $26.50 Million | $67.60 Million | ▲ +257.5% |
| 2014 | -0.25x | $-11.33 Million | $45.54 Million | ▼ -13.0% |
| 2013 | -0.22x | $-13.61 Million | $61.80 Million | — |